<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00325039</url>
  </required_header>
  <id_info>
    <org_study_id>DK58229</org_study_id>
    <nct_id>NCT00325039</nct_id>
  </id_info>
  <brief_title>TOMUS-Trial Of Mid-Urethral Slings</brief_title>
  <acronym>TOMUS</acronym>
  <official_title>TOMUS-Trial Of Mid-Urethral Slings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New England Research Institutes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this clinical trial is to compare treatment success for two minimally
      invasive surgical procedures to treat stress urinary incontinence in women. These procedures
      are called mid-urethral slings. The secondary aims of the trial are to compare other outcomes
      for the two surgical procedures, including quality of life, sexual function, satisfaction
      with treatment outcomes, complications, and the need for other treatments(s) after surgery.
      Follow-up will be a minimum of two years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Treatment Success at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Objective treatment success: negative stress test, negative pad test, and no retreatment for stress urinary incontinence (SUI) including behavioral, pharmacologic or surgical procedures
A provocative stress test standardized to volume and position is performed for direct observation of urine leakage. Observed urine loss from the urethra coincidental with the Valsalva maneuver or cough is a positive test; a negative test indicates no urine loss. Pad testing quantifies the amount of urine involuntarily lost and is used to reflect everyday incontinence; it is negative if loss is &lt;15g/24 hrs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Treatment Success at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Absence of self-reported symptoms of stress-type urinary incontinence, as assessed with the use of the Medical, Epidemiological and Social Aspects of Aging (MESA) questionnaire (responded never to all 9 MESA questions), no leakage recorded in a 3-day voiding diary and no retreatment for stress incontinence including behavioral, pharmacologic or surgical treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction at 12 Months</measure>
    <time_frame>Follow-Up</time_frame>
    <description>Patient satisfaction was assessed at the 12 month visit with the questions, &quot;how satisfied or dissatisfied are you with the result of bladder surgery related to urine leakage?&quot; Possible responses were completely satisfied, mostly satisfied, neutral, mostly dissatisfied, and completely dissatisfied. Completely and mostly satisfied were reported as &quot;satisfied&quot; and neutral, most dissatisfied and completely dissatisfied as &quot;not satisfied&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life From Baseline to 12 Months</measure>
    <time_frame>Baseline - 12 months</time_frame>
    <description>Scores on the Incontinence Impact Questionnaire range from 0 to 400 with higher scores indicating greater impact. The scores are changes from baseline to the 12 month visit (baseline - 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bother as Measured by the Urogenital Distress Inventory (UDI) at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Urogenital Distress Inventory (UDI) scores range from 0 to 300 with higher scores indicating greater distress. Scores are changes from baseline to the 12 month visit (baseline - 12 months)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">597</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>retropubic mid-urethral sling (TVT) The specific TVT used was the Tension-free Vaginal Tape (Gynecare)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>transobturator mid-urethral sling (TVT-O and the Monarc) Two transobturator slings were used: the Tension-free Vaginal Tape Obturator (Gynecare), which is placed starting inside the vagina and coming out through the obturator foramen (&quot;in-to-out&quot;) or the Monarc (American Medical System), which is placed starting in the groin area, passing through the obturator foramen, and then into the vagina (&quot;out-to-in&quot;).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>retropubic mid-urethral sling (TVT)</intervention_name>
    <description>This trial is a comparison of two types of mid-urethral slings. The retropubic mid-urethral mesh sling is used for treatment of stress incontinence; this procedure was less invasive than the fascial sling procedures that were reference standards at the start of the study. Specifically, a synthetic tape is passed transvaginally at the midurethral level through the retropubic space.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transobturator mid-urethral sling (TVT-O and the Monarc)</intervention_name>
    <description>This trial is a comparison of two types of mid-urethral slings. The transobturator mid-urethral sling is used for treatment of stress incontinence; this procedure was developed to minimize the potential for bladder and bowel injuries associated with the retropubic sling, since the sling is passed through the obturator canal, avoiding the pelvic organs in the retropubic space.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Stress urinary incontinence (SUI) as evidenced by all of the following:

          -  Self-reported stress-type urinary incontinence symptoms, of duration ≥ 3 months

          -  Medical, Epidemiological and Social Aspects of Aging (MESA) stress symptom score
             (percent of total possible stress score) greater than MESA urge symptom score (percent
             of total possible urge score)

          -  Observation of leakage by provocative stress test at a bladder volume ≤ 300ml

          -  Bladder capacity ≥ 200ml by stress test

          -  Post-void residual (PVR) ≤ 100cc with pelvic organ prolapse (POP) Stage I or lower. If
             POP is Stage II-IV, PVR &gt;100cc but ≤ 500cc is allowed

          -  Eligible for both retropubic and transobturator procedures

          -  No medical contraindications, e.g., current urinary tract infection (UTI), history of
             pelvic irradiation, history of lower urinary tract cancer

          -  American Society of Anesthesiologists (ASA) class I, II, or III

          -  No current intermittent catheterization

          -  Available for 24-months of follow-up and able to complete study assessments, per
             clinician judgment

          -  Signed consent form

        Exclusion Criteria:

          -  Age &lt;21 years

          -  Non-ambulatory (ambulatory with assistive devices does not exclude the patient)

          -  Pregnancy by self-report or positive pregnancy test, or self-reported intention to
             ever become pregnant

          -  Current chemotherapy or current or history of pelvic radiation therapy

          -  Systemic disease known to affect bladder function (i.e., Parkinson's disease, multiple
             sclerosis, spina bifida, spinal cord injury or trauma)

          -  Urethral diverticulum, current or previous (i.e. repaired)

          -  Prior augmentation cystoplasty or artificial sphincter

          -  Implanted nerve stimulators for urinary symptoms

          -  History of synthetic sling for stress urinary incontinence

          -  &lt;12 months post-partum

          -  Laparoscopic or open pelvic surgery &lt;3 months*

          -  Current evaluation or treatment for chronic pelvic pain (painful bladder syndrome)

          -  Participation in another treatment intervention trial that might influence the results
             of this trial

          -  Need for concomitant surgery requiring an abdominal incision, use of graft material in
             the anterior compartment, or any use of synthetic graft material

          -  Enrollment in other urinary incontinence trials including SISTEr/E-SISTEr or
             BE-DRI/E-BE-DRI
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Gormley, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakwood Hospital/Cancer Center</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.uitn.net/</url>
    <description>Urinary Incontinence Treatment Network Public Website</description>
  </link>
  <reference>
    <citation>Chai TC, Huang L, Kenton K, Richter HE, Baker J, Kraus S, Litman H; Urinary Incontinence Treatment Network (UITN). Association of baseline urodynamic measures of urethral function with clinical, demographic, and other urodynamic variables in women prior to undergoing midurethral sling surgery. Neurourol Urodyn. 2012 Apr;31(4):496-501. doi: 10.1002/nau.21198. Epub 2012 Feb 29.</citation>
    <PMID>22378483</PMID>
  </reference>
  <reference>
    <citation>Nygaard I, Brubaker L, Chai TC, Markland AD, Menefee SA, Sirls L, Sutkin G, Zimmern P, Arisco A, Huang L, Tennstedt S, Stoddard A. Risk factors for urinary tract infection following incontinence surgery. Int Urogynecol J. 2011 Oct;22(10):1255-65. doi: 10.1007/s00192-011-1429-9. Epub 2011 May 11.</citation>
    <PMID>21560012</PMID>
  </reference>
  <reference>
    <citation>Richter HE, Litman HJ, Lukacz ES, Sirls LT, Rickey L, Norton P, Lemack GE, Kraus S, Moalli P, Fitzgerald MP, Dandreo KJ, Huang L, Kusek JW; Urinary Incontinence Treatment Network. Demographic and clinical predictors of treatment failure one year after midurethral sling surgery. Obstet Gynecol. 2011 Apr;117(4):913-21. doi: 10.1097/AOG.0b013e31820f3892.</citation>
    <PMID>21422865</PMID>
  </reference>
  <reference>
    <citation>Chai TC, Kenton K, Xu Y, Sirls L, Zyczynski H, Wilson TS, Rahn DD, Whitcomb EL, Hsu Y, Gormley EA. Effects of concomitant surgeries during midurethral slings (MUS) on postoperative complications, voiding dysfunction, continence outcomes, and urodynamic variables. Urology. 2012 Jun;79(6):1256-61. doi: 10.1016/j.urology.2012.02.048. Epub 2012 Apr 25.</citation>
    <PMID>22542356</PMID>
  </reference>
  <reference>
    <citation>Brubaker L, Norton PA, Albo ME, Chai TC, Dandreo KJ, Lloyd KL, Lowder JL, Sirls LT, Lemack GE, Arisco AM, Xu Y, Kusek JW; Urinary Incontinence Treatment Network. Adverse events over two years after retropubic or transobturator midurethral sling surgery: findings from the Trial of Midurethral Slings (TOMUS) study. Am J Obstet Gynecol. 2011 Nov;205(5):498.e1-6. doi: 10.1016/j.ajog.2011.07.011. Epub 2011 Jul 20.</citation>
    <PMID>21925636</PMID>
  </reference>
  <reference>
    <citation>Nager CW, Sirls L, Litman HJ, Richter H, Nygaard I, Chai T, Kraus S, Zyczynski H, Kenton K, Huang L, Kusek J, Lemack G; Urinary Incontinence Treatment Network. Baseline urodynamic predictors of treatment failure 1 year after mid urethral sling surgery. J Urol. 2011 Aug;186(2):597-603. doi: 10.1016/j.juro.2011.03.105. Epub 2011 Jun 16.</citation>
    <PMID>21683412</PMID>
  </reference>
  <results_reference>
    <citation>Urinary Incontinence Treatment Network (UITN). The Trial of Mid-Urethral Slings (TOMUS): Design and Methodology. J Appl Res. 2008;8(1). pii: AlboVol8No1.</citation>
    <PMID>24772006</PMID>
  </results_reference>
  <results_reference>
    <citation>Brubaker L, Rickey L, Xu Y, Markland A, Lemack G, Ghetti C, Kahn MA, Nagaraju P, Norton P, Chang TD, Stoddard A; Urinary Incontinence Treatment Network. Symptoms of combined prolapse and urinary incontinence in large surgical cohorts. Obstet Gynecol. 2010 Feb;115(2 Pt 1):310-6. doi: 10.1097/AOG.0b013e3181cb86b2.</citation>
    <PMID>20093904</PMID>
  </results_reference>
  <results_reference>
    <citation>Nager CW, Kraus SR, Kenton K, Sirls L, Chai TC, Wai C, Sutkin G, Leng W, Litman H, Huang L, Tennstedt S, Richter HE; Urinary Incontinence Treatment Network. Urodynamics, the supine empty bladder stress test, and incontinence severity. Neurourol Urodyn. 2010 Sep;29(7):1306-11. doi: 10.1002/nau.20836.</citation>
    <PMID>20127832</PMID>
  </results_reference>
  <results_reference>
    <citation>Richter HE, Albo ME, Zyczynski HM, Kenton K, Norton PA, Sirls LT, Kraus SR, Chai TC, Lemack GE, Dandreo KJ, Varner RE, Menefee S, Ghetti C, Brubaker L, Nygaard I, Khandwala S, Rozanski TA, Johnson H, Schaffer J, Stoddard AM, Holley RL, Nager CW, Moalli P, Mueller E, Arisco AM, Corton M, Tennstedt S, Chang TD, Gormley EA, Litman HJ; Urinary Incontinence Treatment Network. Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med. 2010 Jun 3;362(22):2066-76. doi: 10.1056/NEJMoa0912658. Epub 2010 May 17.</citation>
    <PMID>20479459</PMID>
  </results_reference>
  <results_reference>
    <citation>Richter HE, Kenton K, Huang L, Nygaard I, Kraus S, Whitcomb E, Chai TC, Lemack G, Sirls L, Dandreo KJ, Stoddard A. The impact of obesity on urinary incontinence symptoms, severity, urodynamic characteristics and quality of life. J Urol. 2010 Feb;183(2):622-8. doi: 10.1016/j.juro.2009.09.083. Epub 2009 Dec 16.</citation>
    <PMID>20018326</PMID>
  </results_reference>
  <results_reference>
    <citation>Sirls LT, Tennstedt S, Albo M, Chai T, Kenton K, Huang L, Stoddard AM, Arisco A, Gormley EA. Factors associated with quality of life in women undergoing surgery for stress urinary incontinence. J Urol. 2010 Dec;184(6):2411-5. doi: 10.1016/j.juro.2010.08.019. Epub 2010 Oct 16.</citation>
    <PMID>20952014</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2006</study_first_submitted>
  <study_first_submitted_qc>May 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2006</study_first_posted>
  <results_first_submitted>March 26, 2012</results_first_submitted>
  <results_first_submitted_qc>August 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 27, 2012</results_first_posted>
  <last_update_submitted>December 12, 2013</last_update_submitted>
  <last_update_submitted_qc>December 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Incontinence, Stress</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place between April 2006 and June 2008. Patients were recruited from nine clinical sites. TOMUS (Trial Of Mid-Urethral Slings) was conducted by the Urinary Incontinence Treatment Network (UITN), a cooperative network consisting of urologists and urogynecologists at 9 clinical centers and a biostatistical coordinating center.</recruitment_details>
      <pre_assignment_details>3521 women were screened for eligibility. 1513 did not meet inclusion criteria; 1259 were eligible for inclusion in the study but were excluded (1001 declined to participate, 258 excluded for administrative reasons). 749 women provided written consent; of these 152 were excluded (63 ineligible, 66 withdrew consent, 23 administrative reasons).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Retropubic (RMUS)</title>
          <description>retropubic mid-urethral sling (TVT)</description>
        </group>
        <group group_id="P2">
          <title>Transobturator (TMUS)</title>
          <description>transobturator mid-urethral sling (TVT-O and the Monarc)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="298"/>
                <participants group_id="P2" count="299"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="280"/>
                <participants group_id="P2" count="285"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Retropubic (RMUS)</title>
          <description>retropubic mid-urethral sling (TVT)</description>
        </group>
        <group group_id="B2">
          <title>Transobturator (TMUS)</title>
          <description>transobturator mid-urethral sling (TVT-O and the Monarc)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="298"/>
            <count group_id="B2" value="299"/>
            <count group_id="B3" value="597"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Yrs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.7" spread="10.5"/>
                    <measurement group_id="B2" value="53.1" spread="11.5"/>
                    <measurement group_id="B3" value="52.9" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="299"/>
                    <measurement group_id="B3" value="597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="299"/>
                    <measurement group_id="B3" value="597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Treatment Success at 12 Months</title>
        <description>Objective treatment success: negative stress test, negative pad test, and no retreatment for stress urinary incontinence (SUI) including behavioral, pharmacologic or surgical procedures
A provocative stress test standardized to volume and position is performed for direct observation of urine leakage. Observed urine loss from the urethra coincidental with the Valsalva maneuver or cough is a positive test; a negative test indicates no urine loss. Pad testing quantifies the amount of urine involuntarily lost and is used to reflect everyday incontinence; it is negative if loss is &lt;15g/24 hrs.</description>
        <time_frame>12 months</time_frame>
        <population>Because the study was designed as an equivalence trial, the outcome was assessed only in women treated per-protocol (n=291 and n=292 in RMUS, TMUS, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Retropubic (RMUS)</title>
            <description>retropubic mid-urethral sling (TVT)</description>
          </group>
          <group group_id="O2">
            <title>Transobturator (TMUS)</title>
            <description>transobturator mid-urethral sling (TVT-O and the Monarc)</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Treatment Success at 12 Months</title>
          <description>Objective treatment success: negative stress test, negative pad test, and no retreatment for stress urinary incontinence (SUI) including behavioral, pharmacologic or surgical procedures
A provocative stress test standardized to volume and position is performed for direct observation of urine leakage. Observed urine loss from the urethra coincidental with the Valsalva maneuver or cough is a positive test; a negative test indicates no urine loss. Pad testing quantifies the amount of urine involuntarily lost and is used to reflect everyday incontinence; it is negative if loss is &lt;15g/24 hrs.</description>
          <population>Because the study was designed as an equivalence trial, the outcome was assessed only in women treated per-protocol (n=291 and n=292 in RMUS, TMUS, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8"/>
                    <measurement group_id="O2" value="77.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>With 294 women/arm, the study would have 80% power to show equivalence between the two procedures, with an equivalence margin of +/- 12 percentage points, at a two-sided significance level of 5%. A planned time-to-event interim analysis of the primary outcome (objective treatment success) was conducted when 33% of the anticipated treatment failures occurred. We adjusted the primary outcome analysis for this interim look by assigning nominal alpha values of 0.049 to the 95% confidence intervals.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This study was an equivalence trial and was designed to have 80% power to show equivalence between the two sling procedures, with an equivalence margin of +/- 12 percentage points, at a two-sided significance level of 5%. The margin of +/- 12 was chosen on the basis of clinical considerations and a calculation of the number of patients it was feasible to enroll in the trial.</non_inferiority_desc>
            <param_type>difference in success rate (RMUS-TMUS)</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>9.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction at 12 Months</title>
        <description>Patient satisfaction was assessed at the 12 month visit with the questions, &quot;how satisfied or dissatisfied are you with the result of bladder surgery related to urine leakage?&quot; Possible responses were completely satisfied, mostly satisfied, neutral, mostly dissatisfied, and completely dissatisfied. Completely and mostly satisfied were reported as &quot;satisfied&quot; and neutral, most dissatisfied and completely dissatisfied as &quot;not satisfied&quot;.</description>
        <time_frame>Follow-Up</time_frame>
        <population>This is the number of women who answered the satisfaction questions at the 12 month visit (n=280 attended the 12 month visit in the retropubic arm and n=285 in the transobturator arm)</population>
        <group_list>
          <group group_id="O1">
            <title>Retropubic (RMUS)</title>
            <description>retropubic mid-urethral sling (TVT)</description>
          </group>
          <group group_id="O2">
            <title>Transobturator (TMUS)</title>
            <description>transobturator mid-urethral sling (TVT-O and the Monarc)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction at 12 Months</title>
          <description>Patient satisfaction was assessed at the 12 month visit with the questions, &quot;how satisfied or dissatisfied are you with the result of bladder surgery related to urine leakage?&quot; Possible responses were completely satisfied, mostly satisfied, neutral, mostly dissatisfied, and completely dissatisfied. Completely and mostly satisfied were reported as &quot;satisfied&quot; and neutral, most dissatisfied and completely dissatisfied as &quot;not satisfied&quot;.</description>
          <population>This is the number of women who answered the satisfaction questions at the 12 month visit (n=280 attended the 12 month visit in the retropubic arm and n=285 in the transobturator arm)</population>
          <units>percentage of participants analyzed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.9"/>
                    <measurement group_id="O2" value="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Although the primary aim of the study was designed as an equivalence trial, the secondary aims were considered as superiority tests.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <p_value_desc>This was not adjusted for multiple comparisons; the a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>-4.1</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Treatment Success at 12 Months</title>
        <description>Absence of self-reported symptoms of stress-type urinary incontinence, as assessed with the use of the Medical, Epidemiological and Social Aspects of Aging (MESA) questionnaire (responded never to all 9 MESA questions), no leakage recorded in a 3-day voiding diary and no retreatment for stress incontinence including behavioral, pharmacologic or surgical treatment.</description>
        <time_frame>12 months</time_frame>
        <population>Because the study was designed as an equivalence trial, the outcome was assessed only in women treated per-protocol (n=291 in the Retropubic arm and n=292 in the transobturator arm).</population>
        <group_list>
          <group group_id="O1">
            <title>Retropubic (RMUS)</title>
            <description>retropubic mid-urethral sling (TVT)</description>
          </group>
          <group group_id="O2">
            <title>Transobturator (TMUS)</title>
            <description>transobturator mid-urethral sling (TVT-O and the Monarc)</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Treatment Success at 12 Months</title>
          <description>Absence of self-reported symptoms of stress-type urinary incontinence, as assessed with the use of the Medical, Epidemiological and Social Aspects of Aging (MESA) questionnaire (responded never to all 9 MESA questions), no leakage recorded in a 3-day voiding diary and no retreatment for stress incontinence including behavioral, pharmacologic or surgical treatment.</description>
          <population>Because the study was designed as an equivalence trial, the outcome was assessed only in women treated per-protocol (n=291 in the Retropubic arm and n=292 in the transobturator arm).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2"/>
                    <measurement group_id="O2" value="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>With 294 women/arm, the study would have 80% power to show equivalence between the two procedures, with an equivalence margin of +/- 12 percentage points, at a two-sided significance level of 5%. A planned time-to-event interim analysis of the primary outcome (objective treatment success) was conducted when 33% of the anticipated treatment failures occurred. We adjusted the primary outcome analysis for this interim look by assigning nominal alpha values of 0.049 to the 95% confidence intervals.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This study was an equivalence trial and was designed to have 80% power to show equivalence between the two sling procedures, with an equivalence margin of +/- 12 percentage points, at a two-sided significance level of 5%. The margin of +/- 12 was chosen on the basis of clinical considerations and a calculation of the number of patients it was feasible to enroll in the trial.</non_inferiority_desc>
            <param_type>difference in success (RMUS - TMUS)</param_type>
            <param_value>6.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>14.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life From Baseline to 12 Months</title>
        <description>Scores on the Incontinence Impact Questionnaire range from 0 to 400 with higher scores indicating greater impact. The scores are changes from baseline to the 12 month visit (baseline - 12 months).</description>
        <time_frame>Baseline - 12 months</time_frame>
        <population>These are the number of patients with available quality of life data at the 12 month visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Retropubic (RMUS)</title>
            <description>retropubic mid-urethral sling (TVT)</description>
          </group>
          <group group_id="O2">
            <title>Transobturator (TMUS)</title>
            <description>transobturator mid-urethral sling (TVT-O and the Monarc)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life From Baseline to 12 Months</title>
          <description>Scores on the Incontinence Impact Questionnaire range from 0 to 400 with higher scores indicating greater impact. The scores are changes from baseline to the 12 month visit (baseline - 12 months).</description>
          <population>These are the number of patients with available quality of life data at the 12 month visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.8" spread="94.5"/>
                    <measurement group_id="O2" value="132.9" spread="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the two arms do not differ according to quality of life, as measured by the IIQ.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bother as Measured by the Urogenital Distress Inventory (UDI) at 12 Months</title>
        <description>Urogenital Distress Inventory (UDI) scores range from 0 to 300 with higher scores indicating greater distress. Scores are changes from baseline to the 12 month visit (baseline - 12 months)</description>
        <time_frame>12 months</time_frame>
        <population>This is the number of participants who had complete UDI information at the 12 month visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Retropubic (RMUS)</title>
            <description>retropubic mid-urethral sling (TVT)</description>
          </group>
          <group group_id="O2">
            <title>Transobturator (TMUS)</title>
            <description>transobturator mid-urethral sling (TVT-O and the Monarc)</description>
          </group>
        </group_list>
        <measure>
          <title>Bother as Measured by the Urogenital Distress Inventory (UDI) at 12 Months</title>
          <description>Urogenital Distress Inventory (UDI) scores range from 0 to 300 with higher scores indicating greater distress. Scores are changes from baseline to the 12 month visit (baseline - 12 months)</description>
          <population>This is the number of participants who had complete UDI information at the 12 month visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.7" spread="48.0"/>
                    <measurement group_id="O2" value="110.3" spread="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The UDI measure was compared using a two-sample t test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Consistent with the primary outcome reported at 12 months, adverse event data through the 12 month visit are reported here.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Retropubic (RMUS)</title>
          <description>retropubic mid-urethral sling (TVT)</description>
        </group>
        <group group_id="E2">
          <title>Transobturator (TMUS)</title>
          <description>transobturator mid-urethral sling (TVT-O and the Monarc)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Postoperative bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urethral perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Recurrent cystitis, leading to diagnostic cystoscopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Voiding dysfunction requiring surgery, use of catheter or both</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Mesh exposure</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="298"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Mesh erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Surgical site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Granulation tissue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Bladder perforation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Vaginal epithelial perforation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="298"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Urothelial abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Self-reported pain 6 or more weeks after procedure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="298"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Thrush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Medication reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Bilateral leg pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Decreased bladder sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic symptom of numbness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="298"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Neurologic symptom of weakness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="298"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="46" subjects_affected="40" subjects_at_risk="298"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Voiding dysfunction</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="298"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>New urge incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Persistent urge incontinence</sub_title>
                <counts group_id="E1" events="54" subjects_affected="36" subjects_at_risk="298"/>
                <counts group_id="E2" events="55" subjects_affected="30" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Sac in pelvis (seroma)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Mesh exposure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="298"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Surgical site infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="298"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Granulation tissue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="298"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Wound edge separation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Minor wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular or hematologic</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="298"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Heather Litman, PhD</name_or_title>
      <organization>New England Research Institutes, Inc.</organization>
      <phone>617 972 3297</phone>
      <email>hlitman@neriscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

